Andy Blidy

A couple of California stem cells supporters..... Colby Leis my grandson making a statement YESon14.com with Grandpa

@0260n3 @CEO_Culley Why do you say that ? Short term analysis , must be self center and greedy ? Truly not an objective truths , verified and validated analysis , but you have your right to your opinion in the United States ……sort term thinking benefits few

@CEO_Culley Too bad you have not created any value for shareholders.

Stopped for a pic at the Fischli and Weiss “Rock on top of Another Rock”, which evokes the beauty of pushing limits. An inspirational idea applicable to our regenerative medicine mission. Thanks for hosting us in Basel, Roche! $LCTX

@CEO_Culley Time for a franc discussion! 🇨🇭🇨🇭🇨🇭

$LCTX

$NWBO #DCVax

🧠 This “Ultrasound Helmet” Could Change How We Treat Strokes Forever When a stroke blocks blood flow, every minute matters. Scientists are testing a helmet that uses ultrasound waves to shake up clots, helping medicines work faster all without surgery. Early studies suggest it could speed treatment and save brain cells, offering a potential breakthrough in stroke care. Source: Alexandrov, A. V., & Molina, C. A. (2020). Ultrasound-enhanced thrombolysis for acute ischemic stroke. Nature Biomedical Engineering, 4(12), 1120–1128

Longevity progress This is INSANE: Scientists just discovered a hidden organ that influences how long you live For decades, this organ was considered irrelevant in adults. A massive new study has revealed that the thymus, a small immune organ most people ignore after childhood, is one of the strongest predictors of lifespan and disease risk. Researchers analyzed over 27,000 adults using AI-powered CT scan analysis to measure “thymic health” a marker of how well the organ is still functioning. Results were shocking 👀 People with high thymic health had: > 50% lower risk of death > 63% lower risk of cardiovascular death > 36% lower risk of lung cancer The thymus produces T cells, the immune system’s frontline soldiers. As it declines with age, the body loses its ability to fight infections, cancer, and chronic disease. In a second study on cancer patients, those with better thymus function had: > 37% lower disease progression > 44% lower risk of death during immunotherapy This means survival depends not just on the tumor… but on how young your immune system still is. If scientists learn to preserve or restore thymus function, it could unlock longer lifespan, better cancer survival, stronger immunity in old age.

A couple of California stem cells supporters..... Colby Leis my grandson making a statement YESon14.com with Grandpa

Potential of mitochondrial transfer to prevent or treat Parkinson' s disease, in mouse and monkey models @CellCellPress cell.com/cell/fulltext/…

IYCMI: We're trying to crowdfund some of our new exciting brain tumor work. I'd appreciate any support give.ucdavis.edu/CCAD/CC44225 #DIPG #cancer

@CEO_Culley What is with the electric scooter ?

@CEO_Culley Nice to see you two in Basel talking to Roche

Preprint: Treatment of multiple sclerosis with CD19-targeting CAR-T-cells researchsquare.com/article/rs-902… @Clodida

🧬In Cancer Vaccine Push, $NWBO #DCVax Is Already Inside the Room The Agenda and What It Concealed Today, the National Cancer Advisory Board is meeting with a single line item on its agenda: “Scientific Presentation on Cancer Vaccines.” No company named. No platform singled out. No dendritic cell vaccine identified. To anyone scanning the federal register, it read like a general category discussion. That is not what was actually happening. Already Inside the Coalition In the weeks leading up to this meeting, the Cancer Vaccine Coalition, working with AACR, convened a global think tank to accelerate therapeutic cancer vaccines. In its own materials, the Coalition listed Northwest Biotherapeutics as a supporter, used a DCVax-L patient story as a defining example, and publicly embedded the company within the effort shaping the field. AACR went further, thanking Northwest Biotherapeutics as title sponsor of the initiative. That is not peripheral involvement. That is participation at the level of support, sponsorship, and narrative architecture. The question, then, is not whether DCVax is part of the conversation. The record shows that it is. The question is why one of the field’s most mature dendritic cell platforms is present, visible in sponsorship and framing, yet absent from the public facing narrative by name. A Platform That Has Already Crossed the Threshold That omission matters because DCVax-L is not an early stage concept. Northwest Biotherapeutics has stated in regulatory filings that its Phase 3 program was completed, that survival data were published in JAMA Oncology, and that a U.K. marketing application was submitted and validated. The company has moved forward with manufacturing scale up in Sawston, signaling preparation for real world deployment. This is not a theoretical platform waiting for validation. It is a platform that has already crossed into clinical maturity, regulatory engagement, and manufacturing readiness. In a harbor full of vessels still being assembled on the waterline, this one has already been to open sea and returned with data. And yet the official public record of today's NCAB session remains deliberately general. No specifics. No attribution. No platform emphasis. The meeting was publicly noticed. But the framing is controlled. The Harder Truth Behind the Optimism In parallel discussions across the field, experts have suggested that a single clear success could lift the entire cancer vaccine category. All boats could rise. That may well be true. But if that tide is coming, it will not lift all vessels equally. Because not all platforms are built for the same conditions. The same voices that speak of optimism also acknowledge a harder truth. Cancer vaccines tend to perform best in earlier, less immunosuppressed settings. Late stage disease remains difficult. Tumor heterogeneity, immune suppression, and durability remain unresolved. Generating an immune response is no longer the central problem. Sustaining it is. That is the line the field is approaching. And it is precisely at that line that the distinction between payload platforms and dendritic cell platforms becomes unavoidable. Payload Delivery Versus Immune Programming mRNA and similar technologies are exceptionally well suited to initiating responses. They are fast, modular, and scalable. But speed and modularity solve the problem of antigen delivery. They do not solve the problem of what happens after delivery, inside a tumor microenvironment saturated with TGF beta, PD-L1 upregulation, and regulatory T cell infiltration. In that terrain, a payload without upstream immune coordination is a signal sent into a system that has been trained to ignore it. In advanced, cold, heterogeneous tumors, the problem is no longer whether the immune system receives the message. It is whether it has been given the organizational infrastructure to act on it. That is not a payload problem. That is an architectural one. DCVax operates on that level. It is not defined by a single antigen or a delivery vehicle. It is defined by its use of dendritic cells as the control node of immune instruction, by its use of whole tumor lysate to capture antigen breadth, and by its design intent to generate not just response but persistence. The Question the Field Cannot Defer That is why its presence inside this initiative matters. If a national cancer vaccine strategy is now forming, it will eventually have to answer a fundamental question: is this effort about delivering better payloads, or about installing durable immune programs? The current public framing avoids that question. The structure of the field does not. Northwest Biotherapeutics is not knocking on the door of this initiative. It is not waiting to be invited in. It has already been listed, acknowledged, and positioned within the coalition shaping the conversation. It is already in the room. And if the rising tide that many now anticipate does materialize, the more consequential question will not be whether all boats rise. It will be which ones were built for the hardest waters. For a deeper dive and extended analysis, see: x.com/andrewcaravell… This article reflects independent analysis and does not constitute investment advice.

@grok summarize in simple terms and explain the category error described.

A CD138+ tumor-associated macrophage-Siglec-F+ neutrophil feedforward loop promotes immune evasion in pancreatic cancer @jclinicalinvest jci.org/articles/view/… 🇨🇳

@FlemmingBruce @andrewcaravello So what happen at the review ?

$NWBO